Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells

Full text
Author(s):
Show less -
Genvigir, Fabiana Dalla Veccfhia [1] ; Rodrigues, Alice Cristina [1] ; Cerda, Alvaro [1] ; Arazi, Simone Sorkin [1] ; Vieira Willrich, Maria Alice [1] ; Oliveira, Raquel [1] ; Hirata, Mario Hiroyuki [1] ; Dorea, Egidio Lima [2] ; Bernik, Marcia Martins [2] ; Curi, Rui [3] ; Hirata, Rosario Dominguez Crespo [1]
Total Authors: 11
Affiliation:
[1] Univ Sao Paulo, Dept Clin & Toxicol Anal, Sch Pharmaceut Sci, Sao Paulo - Brazil
[2] Univ Sao Paulo, Univ Hosp, Sao Paulo - Brazil
[3] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: PHARMACOGENOMICS; v. 11, n. 9, p. 1235-1246, SEP 2010.
Web of Science Citations: 16
Abstract

Aims: The ATP-binding cassette transporters, ABCA1 and ABCG1, are LXR-target genes that play an important role in reverse cholesterol transport. We examined the effects of inhibitors of the cholesterol absorption (ezetimibe) and synthesis (statins) on expression of these transporters in HepG2 cells and peripheral blood mononuclear cells (PBMCs) of individuals with primary (and nonfamilial) hypercholesterolemia (HC). Materials \& methods: A total of 48 HC individuals were treated with atorvastatin (10 mg/day/4 weeks) and 23 were treated with ezetimibe (10 mg/day/4 weeks), followed by simvastatin (10 mg/day/8 weeks) and simvastatin plus ezetimibe (10 mg of each/day/4 weeks). Gene expression was examined in statin- or ezetimibe-treated and control HepG2 cells as well as PBMCs using real-time PCR. Results: In PBMCs, statins and ezetimibe downregulated ABCA1 and ABCG1 mRNA expression but did not modulate NR1H2 (LxR-beta) and NR1H3 (LXR-alpha) levels. Positive correlations of ABCA1 with ABCG1 and of NR1H2 with NR1H3 expressions were found in all phases of the treatments. In HepG2 cells, ABCA1 mRNA levels remained unaltered while ABCG1 expression was increased by statin (1.0-10.0 mu M) or ezetimibe (5.0 mu M) treatments. Atorvastatin upregulated NR1H2 and NR1H3 only at 10.0 mu M, meanwhile ezetimibe (1.0-5.0 mu M) downregulated NR1H2 but did not change NR1H3 expression. Conclusion: Our findings reveal that lipid-lowering drugs downregulate ABCA1 and ABCG1 mRNA expression in PBMCs of HC individuals and exhibit differential effects on HepG2 cells. Moreover, they indicate that the ABCA1 and ABCG1 transcript levels were not correlated directly to LXR mRNA expression in both cell models treated with lipid-lowering drugs. (AU)

FAPESP's process: 06/06196-0 - Pharmacogenomics study: effects of hypolipidemic drugs on gene expression of transcription factors involved in cholesterol regulation
Grantee:Rosario Dominguez Crespo Hirata
Support type: Regular Research Grants
FAPESP's process: 09/15125-8 - Influence of cholesterol synthesis and absorption on expression of proteins of the cholesterol reverse transport in HepG2 and CACO-2 cells
Grantee:Rosario Dominguez Crespo Hirata
Support type: Regular Research Grants